Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,035 GBX | 0.00% | +1.47% | +52.21% |
Apr. 10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
Apr. 10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
Sales 2023 * | 500K 618K | Sales 2024 * | 2M 2.47M | Capitalization | 133M 164M |
---|---|---|---|---|---|
Net income 2023 * | -7M -8.66M | Net income 2024 * | -7M -8.66M | EV / Sales 2023 * | 251 x |
Net cash position 2023 * | 7.2M 8.91M | Net cash position 2024 * | 15.1M 18.68M | EV / Sales 2024 * | 58.7 x |
P/E ratio 2023 * |
-17.3
x | P/E ratio 2024 * |
-17.3
x | Employees | 78 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 30.4% |
1 week | +1.47% | ||
Current month | +7.81% | ||
1 month | +6.15% | ||
3 months | +60.47% | ||
6 months | +95.28% | ||
Current year | +52.21% |
Managers | Title | Age | Since |
---|---|---|---|
Heikki Lanckriet
CEO | Chief Executive Officer | 47 | 20-12-21 |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Fernández
BRD | Director/Board Member | 64 | - |
David John Roth
DFI | Director of Finance/CFO | 56 | 20-12-21 |
Director/Board Member | 53 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1,035 | 0.00% | 96 |
24-04-18 | 1,035 | 0.00% | 2,421 |
24-04-17 | 1,035 | -3.27% | 564 |
24-04-16 | 1,070 | +1.90% | 1,373 |
24-04-15 | 1,050 | +2.94% | 6,867 |
Delayed Quote London S.E., April 19, 2024 at 11:35 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+52.21% | 165M | |
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
-4.07% | 11.68B | |
+21.36% | 11.6B | |
+8.20% | 11.15B |
- Stock Market
- Equities
- 4BB Stock